Compare Bank of Nova Scotia (BNS) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs ClearPoint Neuro Inc — how do they compare? Bank of Nova Scotia trades at $89.04 (market cap $108.17B), while ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M). The key difference: Bank of Nova Scotia is far larger — about 226× ClearPoint Neuro Inc's market cap, and Bank of Nova Scotia pays a 3.61% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| BNS | CLPT | |
|---|---|---|
Market Cap | $108.17B | $478.63M |
Sector | Financials | Health |
52-Week High | $88.99 | $29.60 |
52-Week Low | $54.50 | $8.66 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $506.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.00, up 0.47% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 earnings beating expectations, revenue growth to $37.1B, and a healthy 24.86% net income margin. Recent acquisition of MapleMark Bank supports strategic growth initiatives while the dividend increase to $1.14 signals management confidence.
BNS presents a compelling investment case with consistent earnings beats, attractive dividend yield, and strategic expansion. However, elevated valuation multiples and macroeconomic sensitivity in the banking sector warrant caution. Analyst consensus remains positive with 53% buy ratings, though the stock trades near resistance levels requiring careful entry timing.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
